CAR-T cell therapy for refractory lupus with or without kidney involvement
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 70 years old.
- You have been diagnosed with lupus (SLE) for at least 6 months.
- You have tried at least 2 standard lupus treatments for 3 months each without enough improvement.
- Your lupus is active, shown by a score of at least 7 on a standard lupus activity scale.
- If you have lupus nephritis, you need a recent kidney biopsy showing class III or IV (with or without class V).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests a new treatment called CD19 CAR-T cell therapy for people with severe lupus nephritis (lupus-related kidney inflammation) that hasn't improved with usual treatments. The therapy uses your own immune cells to target and possibly reset the immune system, which may reduce kidney damage and help control the disease.
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
This trial tests a new treatment called C-CAR168, which uses your own immune cells to target and calm the part of the immune system attacking your kidneys. It is designed for people with lupus nephritis that has not improved with usual treatments.
This study tests a new type of treatment called CAR-T cells, which are specially engineered immune cells that may help control lupus by targeting the cells causing the disease. If you have active lupus despite standard treatments, this therapy might offer a new option to reduce symptoms and improve your condition.
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.